Cargando…

WITHDRAWN: A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.

Detalles Bibliográficos
Autores principales:	Rose, Jessica, McCullough, Peter A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mosby-Year Book 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483988/ https://www.ncbi.nlm.nih.gov/pubmed/34601006 http://dx.doi.org/10.1016/j.cpcardiol.2021.101011

Ejemplares similares

Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports
por: Riad, Abanoub, et al.
Publicado: (2022)

The temporal relationship between RotaTeq immunization and intussusception adverse events in the Vaccine Adverse Event Reporting System (VAERS)
por: Geier, David A., et al.
Publicado: (2012)

Adverse event detection by integrating twitter data and VAERS
por: Wang, Junxiang, et al.
Publicado: (2018)

Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics’ impact
por: Almadani, Ohoud A., et al.
Publicado: (2022)

Profiling COVID-19 Vaccine Adverse Events by Statistical and Ontological Analysis of VAERS Case Reports
por: Guo, Wenxin, et al.
Publicado: (2022)

Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case–control assessment of the vaccine adverse event reporting system (VAERS) database
por: Geier, David A., et al.
Publicado: (2016)

COVID-19 vaccine and menstrual conditions in female: data analysis of the Vaccine Adverse Event Reporting System (VAERS)
por: Zhang, Bing, et al.
Publicado: (2022)

Ontology-based time information representation of vaccine adverse events in VAERS for temporal analysis
por: Tao, Cui, et al.
Publicado: (2012)

Identification of sex-associated network patterns in Vaccine-Adverse Event Association Network in VAERS
por: Zhang, Yuji, et al.
Publicado: (2015)

Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 – October 2021
por: Moro, Pedro L., et al.
Publicado: (2022)

EPH174 Adverse Events Associated with COVID-19 and Seasonal Influenza Vaccines: A Retrospective and Descriptive Analysis of CDC/FDA Vaccine Adverse Event Reporting System (VAERS) Reports
por: Alqahtani, Z, et al.
Publicado: (2022)

Linked vaccine adverse event data from VAERS for biomedical data analysis and longitudinal studies
por: Tao, Cui, et al.
Publicado: (2014)

Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)
por: Welsh, Kerry J., et al.
Publicado: (2021)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Trivalent Influenza Vaccine Adverse Event Analysis Based On MedDRA System Organ Classes Using VAERS Data
por: Tao, Cui, et al.
Publicado: (2015)

Relative trends in hospitalizations and mortality among infants by the number of vaccine doses and age, based on the Vaccine Adverse Event Reporting System (VAERS), 1990–2010
por: Goldman, GS, et al.
Publicado: (2012)

Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015
por: Moro, Pedro L., et al.
Publicado: (2016)

Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database
por: Falotico, Julianne M., et al.
Publicado: (2022)

EPH106 Comparison of the Post-Marketing Safety Profile between Influenza and COVID-19 Vaccines: An Analysis of the Vaccine Adverse Event Reporting System (VAERS)
por: Alahmari, AK, et al.
Publicado: (2022)

COVID-19 vaccine adverse events in a population aged 5–17 years: a study from the VAERS database
por: Villa-Zapata, Lorenzo, et al.
Publicado: (2023)

Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System
por: Jones, S. Christopher, et al.
Publicado: (2015)

EPH139 COVID-19 Vaccine Related Adverse Events in a Population Aged 5–17 Years: A Study of Reports from the VAERS Database
por: Lee, Y, et al.
Publicado: (2022)

Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017
por: Dores, Graça M., et al.
Publicado: (2019)

2463. Post-licensure Surveillance of 9-Valent Human Papillomavirus Vaccine (9vHPV) in the Vaccine Adverse Event Reporting System (VAERS), United States, 2014–2017
por: Arana, Jorge, et al.
Publicado: (2018)

Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration’s Adverse Event Reporting System from 2016 to 2021
por: Learned, Christine, et al.
Publicado: (2022)

Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events
por: Yu, Yue, et al.
Publicado: (2016)

Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013−May 31, 2015
por: Haber, Penina, et al.
Publicado: (2016)

Adverse Events Associated with Use of Digoxin Immune Fab Reported to the US Food and Drug Administration Adverse Event Reporting System, 1986–2019
por: Wei, Shaokui, et al.
Publicado: (2021)

Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System
por: Jeon, Minji, et al.
Publicado: (2021)

Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021–June 30, 2022
por: Moro, Pedro L., et al.
Publicado: (2023)

Characteristics of Adverse Events Following Immunization Reporting in Children: The Japanese Adverse Drug Event Report Database
por: Noda, Aoi, et al.
Publicado: (2020)

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
por: Kato, Yamato, et al.
Publicado: (2015)

Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database
por: Nagai, Junko, et al.
Publicado: (2021)

The Ontology of Vaccine Adverse Events (OVAE) and its usage in representing and analyzing adverse events associated with US-licensed human vaccines
por: Marcos, Erica, et al.
Publicado: (2013)

Categorisation of Pharmaceutical Adverse Events Using the Japanese Adverse Drug Event Report Database: Characteristic Adverse Drug Events of the Elderly Treated with Polypharmacy
por: Negishi, Akio, et al.
Publicado: (2020)

Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems
por: Han, Nayoung, et al.
Publicado: (2021)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Adverse event profiles of microscopic colitis in the Japanese Adverse Drug Event Report (JADER) database
por: Yamashiro, Kaito, et al.
Publicado: (2022)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Completeness of adverse drug reactions reports of the Saudi adverse event reporting system
por: Alshammari, Thamir M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gg8p4gnasmrtaurkk074bhtvvg